Falkai, Peter Gaston

[["dc.bibliographiccitation.firstpage","142"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","The World Journal of Biological Psychiatry"],["dc.bibliographiccitation.lastpage","170"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Lieberman, Jeffrey"],["dc.contributor.author","Glenthoj, Birte"],["dc.contributor.author","Gattaz, Wagner F."],["dc.contributor.author","Thibaut, Florence"],["dc.contributor.author","Moeller, Hans-Juergen"],["dc.date.accessioned","2018-11-07T09:59:10Z"],["dc.date.available","2018-11-07T09:59:10Z"],["dc.date.issued","2015"],["dc.description.abstract","These updated guidelines are based on the first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in the years 2005 and 2006. For this 2015 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations which are clinically and scientifically relevant. They are intended to be used by all physicians diagnosing and treating patients with schizophrenia. Based on the first version of these guidelines a systematic review, as well as a data extraction from national guidelines have been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and subsequently categorised into six levels of evidence (A-F) and five levels of recommendation (1-5). This third part of the updated guidelines covers the management of the following specific treatment circumstances: comorbid depression, suicidality, various comorbid substance use disorders (legal and illegal drugs), and pregnancy and lactation. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of patients with schizophrenia."],["dc.identifier.doi","10.3109/15622975.2015.1009163"],["dc.identifier.isi","352078300002"],["dc.identifier.pmid","25822804"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37530"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Informa Healthcare"],["dc.relation.issn","1814-1412"],["dc.relation.issn","1562-2975"],["dc.title","World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","17"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Der Nervenarzt"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","79"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","D'Amelio, R."],["dc.contributor.author","Falkai, Peter Gaston"],["dc.date.accessioned","2018-11-07T11:20:28Z"],["dc.date.available","2018-11-07T11:20:28Z"],["dc.date.issued","2008"],["dc.description.abstract","Substance use disorder is the most common psychiatric comorbidity in patients with schizophrenia, revealing prevalence rates of up to 65%. Recommendations of antipsychotic pharmacotherapy in schizophrenia are based on studies excluding patients with this double diagnosis. In this systematic review the available pharmacological studies in this subgroup of patients are summarised and discussed with regard to evidence-based medicine. Most available studies concern small sample sizes, and the level of evidence in those studies was low. Data suggest efficacy for second-generation antipsychotics (SGAs) (aripiprazole, clozapine, olanzapine, quetiapine, and risperidone) superior to orally administered conventional antipsychotics. Treatment with SGAs revealed superior improvement of distinct psychopathological symptoms, similarly to those studies excluding patients with comorbid substance abuse. In some studies reduced craving and increased reduction of substance abuse could be demonstrated. Tricyclic antidepressants (TCAs) added to antipsychotic maintenance therapy showed efficacy in reducing substance abuse and craving, whereas studies with other antidepressive agents (e.g. selective serotonin reuptake inhibitors) are lacking. Administration of the anti-craving agents naltrexone and disulfiram led to a decrease of drug intake in a few studies. Unfortunately no studies are available using acamprosate in patients with schizophrenia and comorbid alcoholism. In conclusion the preferential use of SGAs in patients with schizophrenia and comorbid substance use disorder is suggested, and the early initiation of concomitant treatment with TCAs (depending on current psychopathological status) and anti-craving agents has to be considered."],["dc.identifier.doi","10.1007/s00115-007-2310-4"],["dc.identifier.isi","000252467600002"],["dc.identifier.pmid","17619840"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55540"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0028-2804"],["dc.title","Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1226"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Neuropsychopharmacology"],["dc.bibliographiccitation.lastpage","1238"],["dc.bibliographiccitation.volume","35"],["dc.contributor.author","Barakauskas, Vilte E."],["dc.contributor.author","Beasley, Clare L."],["dc.contributor.author","Barr, Alasdair M."],["dc.contributor.author","Ypsilanti, Athena R."],["dc.contributor.author","Li, Hong-Ying"],["dc.contributor.author","Thornton, Allen E."],["dc.contributor.author","Wong, Hubert"],["dc.contributor.author","Rosokilja, Gorazd"],["dc.contributor.author","Mann, Johannes F. E."],["dc.contributor.author","Mancevski, Branislav"],["dc.contributor.author","Jakovski, Zlatko"],["dc.contributor.author","Davceva, Natasha"],["dc.contributor.author","Ilievski, Boro"],["dc.contributor.author","Dwork, Andrew J."],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Honer, William G."],["dc.date.accessioned","2018-11-07T08:44:47Z"],["dc.date.available","2018-11-07T08:44:47Z"],["dc.date.issued","2010"],["dc.description.abstract","Abnormalities of amount and function of presynaptic terminals may have an important role in the mechanism of illness in schizophrenia. The SNARE proteins (SNAP-25, syntaxin, and VAMP) are enriched in presynaptic terminals, where they interact to form a functional complex to facilitate vesicle fusion. SNARE protein amounts are altered in the cortical regions in schizophrenia, but studies of protein protein interactions are limited. We extended these investigations to the striatal regions (such as the nucleus accumbens, ventromedial caudate (VMC), and dorsal caudate) relevant to disease symptoms. In addition to measuring SNARE protein levels, we studied SNARE protein-protein interactions using a novel ELISA method. The possible effect of antipsychotic treatment was investigated in parallel in the striatum of rodents that were administered haloperidol and clozapine. In schizophrenia samples, compared with controls, SNAP-25 was 32% lower (P = 0.015) and syntaxin was 26% lower (P = 0.006) in the VMC. In contrast, in the same region, SNARE protein-protein interactions were higher in schizophrenia (P = 0.008). Confocal microscopy of schizophrenia and control VMC showed qualitatively similar SNARE protein immunostaining. Haloperidol treatment of rats increased levels of SNAP-25 (mean 24%, P = 0.003), syntaxin (mean 18%, P = 0.010), and VAMP (mean 16%, P = 0.001), whereas clozapine increased only the VAMP level (mean 13%, P = 0.004). Neither drug altered SNARE protein-protein interactions. These results indicate abnormalities of amount and interactions of proteins directly related to presynaptic function in the VMC in schizophrenia. SNARE proteins and their interactions may be a novel target for the development of therapeutics. Neuropsychopharmacology (2010) 35, 1226-1238; doi: 10.1038/npp.2009.228; published online 13 January 2010"],["dc.identifier.doi","10.1038/npp.2009.228"],["dc.identifier.isi","000275648000017"],["dc.identifier.pmid","20072114"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20278"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","0893-133X"],["dc.title","A Novel Mechanism and Treatment Target for Presynaptic Abnormalities in Specific Striatal Regions in Schizophrenia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","7S_Part_1"],["dc.bibliographiccitation.journal","Alzheimer's & Dementia"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Franzmeier, Nicolai"],["dc.contributor.author","Wolfsgruber, Steffen"],["dc.contributor.author","Ramirez, Alfredo"],["dc.contributor.author","Wagner, Michael"],["dc.contributor.author","Buerger, Katharina"],["dc.contributor.author","Dichgans, Martin"],["dc.contributor.author","Heneka, Michael"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Teipel, Stefan J."],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Ewers, Michael"],["dc.date.accessioned","2021-12-08T12:27:22Z"],["dc.date.available","2021-12-08T12:27:22Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1016/j.jalz.2017.06.2302"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/95331"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-476"],["dc.relation.eissn","1552-5279"],["dc.relation.issn","1552-5260"],["dc.rights.uri","http://onlinelibrary.wiley.com/termsAndConditions#vor"],["dc.title","[IC‐P‐030]: Connectivity of the Left Frontal Cortex Attenuates Detrimental Effects of Csf‐Tau on Memory in Preclinical and Clinical Alzheimer's Disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Psychiatry"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Tomas-Roig, Jordi"],["dc.contributor.author","Piscitelli, Fabiana"],["dc.contributor.author","Di Marzo, Vincenzo"],["dc.contributor.author","Del Rio, J. A."],["dc.contributor.author","Falkai, Peter Gaston"],["dc.date.accessioned","2018-11-07T09:45:27Z"],["dc.date.available","2018-11-07T09:45:27Z"],["dc.date.issued","2014"],["dc.identifier.isi","000347280701241"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34621"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier France-editions Scientifiques Medicales Elsevier"],["dc.publisher.place","Paris"],["dc.relation.issn","1778-3585"],["dc.relation.issn","0924-9338"],["dc.title","PSYCHOSOCIAL STRESS AND PSYCHIATRIC PHENOTYPES: ENDOCANNABINOIDS AND CANNABINOID RECEPTOR (CBR) EXPRESSION IN CORTICO-STRIATAL CONNECTIVITY"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","366"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Experimental Neurology"],["dc.bibliographiccitation.lastpage","370"],["dc.bibliographiccitation.volume","223"],["dc.contributor.author","Lewczuk, Piotr"],["dc.contributor.author","Kornhuber, Johannes"],["dc.contributor.author","Vanmechelen, Eugeen"],["dc.contributor.author","Peters, Oliver"],["dc.contributor.author","Heuser, Isabella"],["dc.contributor.author","Maier, Wolfgang"],["dc.contributor.author","Jessen, Frank"],["dc.contributor.author","Buerger, Katharina"],["dc.contributor.author","Hampel, Harald"],["dc.contributor.author","Froelich, Lutz"],["dc.contributor.author","Henn, Fritz A."],["dc.contributor.author","Falkai, Peter Gaston"],["dc.contributor.author","Ruether, Eckhart"],["dc.contributor.author","Jahn, Holger"],["dc.contributor.author","Luckhaus, C. H."],["dc.contributor.author","Perneczky, Robert"],["dc.contributor.author","Schmidtke, K."],["dc.contributor.author","Schroeder, J."],["dc.contributor.author","Kessler, H."],["dc.contributor.author","Pantel, Johannes"],["dc.contributor.author","Gertz, H.-J."],["dc.contributor.author","Vanderstichele, Hugo"],["dc.contributor.author","de Meyer, G."],["dc.contributor.author","Shapiro, F."],["dc.contributor.author","Wolf, S."],["dc.contributor.author","Bibl, Mirko"],["dc.contributor.author","Wiltfang, J."],["dc.date.accessioned","2018-11-07T08:42:36Z"],["dc.date.available","2018-11-07T08:42:36Z"],["dc.date.issued","2010"],["dc.description.abstract","We measured concentrations of to peptides 1-42 and 1-40, and their ratio in plasma of patients carefully categorized clinically and neurochemically as having AD or other dementias with a newly commercially available multiplexing assay, characterized by reasonable laboratory performance (intra-assay imprecision in the range of 1.3-3.8% for A beta 1-42, and 1.8-4.1% for A beta 1-40, inter-assay imprecision for A beta 1-42, A beta 1-40, and A beta 1-42/A beta 1-40 concentration ratio in the range of 2.3-11.5%, 2.2-10.4% and 42-9.7%, respectively). Patients with AD or mild cognitive impairment of AD type (MCI-AD) whose clinical diagnosis was supported with CSF biomarkers (n = 193) had significantly lower A beta 1-42 plasma concentrations (p<0.007), and A beta 1-42/1-40 ratios (p<0.003) compared to patients with other dementias and MCI of other types (n = 64). No significant differences between persons with MCI of AD type and patients with early AD were observed, or between MCI of other types versus patients with early dementia of other types. Our findings reconfirm the hypothesis that alterations of biomarker concentrations occur early in a preclinical AD stage and that these alterations are also reflected in plasma. (C) 2009 Published by Elsevier Inc."],["dc.identifier.doi","10.1016/j.expneurol.2009.07.024"],["dc.identifier.isi","000277743700015"],["dc.identifier.pmid","19664622"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19739"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Academic Press Inc Elsevier Science"],["dc.relation.issn","0014-4886"],["dc.title","Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","719"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","The World Journal of Biological Psychiatry"],["dc.bibliographiccitation.lastpage","728"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Martins-De-Souza, Daniel"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Schmitt, Andrea"],["dc.contributor.author","Gawinecka, Joanna"],["dc.contributor.author","Schneider-Axmann, Thomas"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Turck, Christoph W."],["dc.date.accessioned","2018-11-07T08:41:14Z"],["dc.date.available","2018-11-07T08:41:14Z"],["dc.date.issued","2010"],["dc.description.abstract","Objectives. To identify proteins differentially expressed in schizophrenia patients, we collected 50 mu l cerebrospinal fluid from 17 first-episode schizophrenia patients and 10 healthy controls. Methods. Their proteins were separated by two-dimensional gel electrophoresis without using any depletion method and identified by mass spectrometry. Results. Approximately 550 spots were detected, six of which had significantly different intensities in schizophrenia compared to control specimens. We were able to validate in individual samples the upregulation of apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase by Western blot analyses and detect the downregulation of transthyretin, TGF-beta receptor type-1 and coiled-coil domain-containing protein 3 precursor. Conclusions. These findings may help to elucidate the disease mechanisms and confirm the hypothesis of disturbed cholesterol and phospholipid metabolism in schizophrenia, and thus reveal the final role players. Moreover, a grouped protein expression analysis of apolipoprotein E, apolipoprotein A-I, and prostaglandin-H2 D-isomerase in cerebrospinal fluid from patients might be a potential diagnostic tool for schizophrenia."],["dc.identifier.doi","10.3109/15622971003758748"],["dc.identifier.isi","000280009300005"],["dc.identifier.pmid","20446881"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19420"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Informa Healthcare"],["dc.relation.issn","1562-2975"],["dc.title","Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","397"],["dc.bibliographiccitation.journal","Schizophrenia Research"],["dc.bibliographiccitation.lastpage","407"],["dc.bibliographiccitation.volume","216"],["dc.contributor.author","Takahashi, Shun"],["dc.contributor.author","Keeser, Daniel"],["dc.contributor.author","Rauchmann, Boris-Stephan"],["dc.contributor.author","Schneider-Axmann, Thomas"],["dc.contributor.author","Keller-Varady, Katriona"],["dc.contributor.author","Maurus, Isabel"],["dc.contributor.author","Dechent, Peter"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Schmitt, Andrea"],["dc.contributor.author","Ertl-Wagner, Birgit"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Falkai, Peter"],["dc.date.accessioned","2021-04-14T08:27:38Z"],["dc.date.available","2021-04-14T08:27:38Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1016/j.schres.2019.11.004"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82355"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.issn","0920-9964"],["dc.title","Effect of aerobic exercise combined with cognitive remediation on cortical thickness and prediction of social adaptation in patients with schizophrenia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","365"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Psychiatrische Praxis"],["dc.bibliographiccitation.lastpage","367"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Mueller, Juergen Leo"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Schneider, Frank"],["dc.contributor.author","Hauth, Iris"],["dc.contributor.author","Maier, Wolfgang"],["dc.date.accessioned","2018-11-07T09:18:48Z"],["dc.date.available","2018-11-07T09:18:48Z"],["dc.date.issued","2013"],["dc.identifier.doi","10.1055/s-0033-1349560"],["dc.identifier.isi","000330534100003"],["dc.identifier.pmid","24101137"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28485"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","1439-0876"],["dc.relation.issn","0303-4259"],["dc.title","Psychiatry Caught Between Emergency Response and Therapy: Compulsory Treatment Following the Jurisprudence of the Federal Constitutional Court and the Federal Supreme Court"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Gruber, Oliver"],["dc.contributor.author","Meyer, J."],["dc.contributor.author","Zilles, David"],["dc.contributor.author","Gruber, Eva"],["dc.contributor.author","Falkai, Peter Gaston"],["dc.date.accessioned","2018-11-07T10:59:21Z"],["dc.date.available","2018-11-07T10:59:21Z"],["dc.date.issued","2007"],["dc.format.extent","221"],["dc.identifier.isi","000249873600085"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50679"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","25th Symposium of the Arbeitsgemeinschaft-Neuropsychopharmakologie-und-Pharmakopsychiatrie"],["dc.relation.eventlocation","Munich, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Genetic polymorphisms of serotonergic and dopaminergic neurotransmission differentially affect neurofunctional subsystems of working memory"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]